Literature DB >> 18509273

Evaluation of clinical outcomes and prognostic factors for synovial sarcoma arising from the extremities.

Tomoya Sakabe1, Hiroaki Murata, Eiichi Konishi, Hideyuki Takeshita, Hideki Ueda, Takaaki Matsui, Naoyuki Horie, Akio Yanagisawa, Toshikazu Kubo.   

Abstract

BACKGROUND: Synovial sarcoma is an uncommon tumor and remains a disease with poor prognosis. Although several prognostic factors have been previously reported, prognostic factors associated with synovial sarcoma are conflicting. This study was undertaken to evaluate our institutional clinical outcomes and to determine prognostic factors for synovial sarcoma. MATERIAL/
METHODS: A series of 17 patients with synovial sarcoma arising from the extremities surgically treated between September 1979 and April 2005 was analyzed retrospectively. Data regarding patient age, sex, primary tumor site, primary tumor size, histologic subtype, management of primary tumor (surgery, chemotherapy, radiotherapy), microscopic surgical margins, previous treatment at other hospitals for synovial sarcoma and follow-up information were recorded. Furthermore, statistical analysis of survival rates and prognostic variables were examined.
RESULTS: The mean and median follow-up time were 82.4 months and 79.0 months, respectively. Seven of 17 patients (41.2%) initially underwent inappropriate unplanned surgery at other hospitals. The surgical margins of the definitive surgery at our hospital were adequate in all patients. The local recurrence and metastasis rates after definite surgery with adequate surgical margins at our hospital were 5.9% and 35.3%, respectively. The 5-year and 10-year overall survival rates were 88.2% and 79.4%, respectively. A statistically significant adverse prognostic factor was undergoing initial surgical resection at other hospitals (p=0.02).
CONCLUSIONS: Initial surgical treatment with adequate surgical margins by experienced surgeons for synovial sarcomas, preferably at specialized hospitals, should be considered to increase local control and improve outcome and survival.

Entities:  

Mesh:

Year:  2008        PMID: 18509273

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  5 in total

1.  Synovial sarcoma in patients under 20 years of age: a multicenter study with a minimum follow-up of 10 years.

Authors:  Bernhard M Speth; Andreas H Krieg; Andre Kaelin; G Ulrich Exner; Louis Guillou; Arthur von Hochstetter; Gernot Jundt; Fritz Hefti
Journal:  J Child Orthop       Date:  2011-08-11       Impact factor: 1.548

Review 2.  Primary synovial sarcomas of the mediastinum: a systematic review and pooled analysis of the published literature.

Authors:  Samer Salah; Ahmed Salem
Journal:  ISRN Oncol       Date:  2014-01-20

3.  Essential role of mitogen-activated protein kinases in IL-17A-induced MMP-3 expression in human synovial sarcoma cells.

Authors:  Takuma Sakurai; Daigo Yoshiga; Wataru Ariyoshi; Toshinori Okinaga; Hiroyasu Kiyomiya; Junya Furuta; Izumi Yoshioka; Kazuhiro Tominaga; Tatsuji Nishihara
Journal:  BMC Res Notes       Date:  2016-02-05

4.  Reasons why a second radiological opinion is advisable: a case report of a misreported crural synovial cell sarcoma.

Authors:  Rocco Severino; Paolo Severino
Journal:  J Surg Case Rep       Date:  2017-03-09

5.  Synovial Sarcoma: A Clinicopathological and Radiological Study of 12 Cases Seen Over 18 Years.

Authors:  Soumaya Ben Abdelkrim; Amel Trabelsi; Faten Hammedi; Mohamed Zaher Boudagga; Ahlem Bdioui; Wafa Jomaa; Moncef Mokni
Journal:  World J Oncol       Date:  2010-02-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.